

Optimising survival in metastatic castration-resistant prostate cancer (mCRPC)

Industry session by SANOFI GENZYME

Friday, 24 March
16:15 - 17:45

Location: Room London, North Hall (Level 1)

Chair: B. Tombal, Brussels (BE)

16:15 - 16:20

Welcome and introduction

B. Tombal, Brussels (BE)

16:20 - 16:40

Are we targeting prostate cancer heterogeneity in the right way?

B. Tombal, Brussels (BE)

16:40 - 17:00

mCRPC in 2017 - Lessons from clinical trials and perspectives

J. De Bono, Sutton (GB)

17:00 - 17:20

mCRPC in 2017 - From clinical trials to real-life practice

S. Oudard, Paris (FR)

17:20 - 17:40

mCRPC in 2017 - A closer look to senior adults

N. Mottet, Saint-Étienne (FR)

17:40 - 17:45

Discussion and closing remarks

B. Tombal, Brussels (BE)